<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02267317</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20140498H</org_study_id>
    <nct_id>NCT02267317</nct_id>
  </id_info>
  <brief_title>The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects</brief_title>
  <acronym>Eritoran2</acronym>
  <official_title>Phase 2 Study of The Role of Pharmacologic Inhibition of TLR4 With E5564 on Glucose Metabolism in Insulin Resistant Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran
      for injection (E5564) will reduce inflammation and improve glucose metabolism in insulin
      resistant (obese and T2DM) subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      E5564 = Eritoran
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study drug expired
  </why_stopped>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participant, Care Provider, Investigator, Outcomes Assessor</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Eritoran on Muscle Insulin Sensitivity</measure>
    <time_frame>72 hours</time_frame>
    <description>Muscle insulin sensitivity = muscle insulin sensitivity is determined by euglycemic hyperinsulinemic clamp procedure. M value (mg glucose / kg of body weight / minute) calculated from the clamp is measured. Higher M value indicates better insulin sensitivity. There is no established reference range.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Eritoran on Hepatic Insulin Sensitivity</measure>
    <time_frame>72 hours</time_frame>
    <description>Hepatic insulin sensitivity = is determined by euglycemic hyperinsulinemic clamp procedure. Endogenous glucose production or EGP (mg/kg/min) calculated from the clamp is measured. Lower EGP indicates better hepatic insulin sensitivity. There is no established reference range.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Eritoran on TLR4 Expression in Muscle Tissue</measure>
    <time_frame>72 hours</time_frame>
    <description>TLR4 expression in muscle tissue is determined by RNAseq using arbitrary units. Higher TLR4 expression indicates higher inflammatory response. There is no reference range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Eritoran on TLR4 Expresison in Adipose Tissue</measure>
    <time_frame>72 hours</time_frame>
    <description>TLR4 expression in the adipose tissue is determined by RNAseq using arbitrary units. Higher TLR4 expression indicates higher inflammatory response. There is no reference range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Eritoran on TLR4 Expression in Peripheral Blood Monocytes</measure>
    <time_frame>72 hours</time_frame>
    <description>TLR4 expression in the peripheral blood monocytes is determined by flow cytometry using arbitrary units. Higher TLR4 expression indicates higher inflammatory response. There is no reference range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Eritoran on Plasma TNF-alpha (Tumor Necrosis Factor-alpha) Concentration</measure>
    <time_frame>72 hours</time_frame>
    <description>TNF-alpha levels are determined by ELISA. Higher level indicates higher inflammatory response. There is no established reference range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Eritoran on Intramyocellular Diacylglycerol and Ceramide Content</measure>
    <time_frame>72 hours</time_frame>
    <description>Intramyocellular diacylglycerol and ceramide content are determined by mass spectrometry. Higher levels have been associated with diabetes.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>Obese Group-D5W</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obese subjects receive IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese Group - Eritoran</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obese subjects receive IV administration of Eritoran 12 mg every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes (T2DM) Group - D5W</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>T2DM subjects receive IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes (T2DM) Group - Eritoran</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>T2DM subjects receive IV administration of Eritoran 12 mg every 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eritoran</intervention_name>
    <description>Pharmacologic inhibitor of TLR4 receptors.</description>
    <arm_group_label>Diabetes (T2DM) Group - Eritoran</arm_group_label>
    <arm_group_label>Obese Group - Eritoran</arm_group_label>
    <other_name>E5564</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D5W</intervention_name>
    <description>5% Dextrose Water = Vehicle</description>
    <arm_group_label>Diabetes (T2DM) Group - D5W</arm_group_label>
    <arm_group_label>Obese Group-D5W</arm_group_label>
    <other_name>Placebo, Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects capable of giving informed consent.

          -  lean (BMI &lt;26 kg/m2) with normal glucose-tolerant subjects without a family history of
             type 2 DM

          -  obese (BMI 30-37 kg/m2) with normal glucose-tolerant subjects

          -  Type 2 DM subjects base on ADA criteria, who have HbA1c &lt;8.5% and control with diet or
             sulfonylureas.

          -  Both genders. (50% males)

          -  Age = 18-65 years. Older subjects are excluded because aging is a pro-inflammatory
             state.

          -  All ethnic groups

          -  Premenopausal women in the follicular phase, non-lactating, and with a negative
             pregnancy test. Postmenopausal women on stable dose of or not exposed to hormone
             replacement for &gt;=6 months.

          -  Lab: Hematocrit &gt;=34%, serum creatinine &lt;=1.4 mg/dL, normal electrolytes, urinalysis,
             and coagulation tests. Liver function tests up to 2x normal range.

          -  Stable body weight (+/-1%) for &gt;=3 months.

          -  One or less sessions of strenuous exercise/wk for last 6 months.

        Exclusion Criteria:

          -  Current treatment with drugs known to affect glucose and lipid homeostasis. Subjects
             on a stable dose of statin (&gt;3 months) are eligible.

          -  Non-steroidal anti-inflammatory drugs or systemic steroid use for more than 1 week
             within 3 months.

          -  Current treatment with anticoagulants (warfarin). Aspirin (up to 325 mg) and
             clopidogrel will be permitted if these can be held for seven days prior to the
             biopsies.

          -  History of heart disease (New York Heart Classification greater than class II; more
             than non-specific ST-T wave changes on the ECG), peripheral vascular disease,
             pulmonary disease, smokers.

          -  Poorly controlled blood pressure (systolic BP&gt;160, diastolic BP&gt;90 mmHg).

          -  Active inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignant, and
             psychiatric disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Musi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Audie L. Murphy VA Hospital, STVHCS San Antonio, Texas, United States 78229</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Audie L. Murphy VA Hospital, STVHCS</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 26, 2014</study_first_submitted>
  <study_first_submitted_qc>October 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <results_first_submitted>January 22, 2020</results_first_submitted>
  <results_first_submitted_qc>February 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 4, 2020</results_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin signaling and glucose disposal in muscle</keyword>
  <keyword>Hepatic insulin sensitivity</keyword>
  <keyword>TLR4 signaling and inflammatory gene expression</keyword>
  <keyword>Plasma cytokine concentration</keyword>
  <keyword>Intramyocellular diacylglycerol and ceramide content</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 10, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02267317/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Obese Group - D5W - Eritoran</title>
          <description>Obese subjects randomized to receive D5W first, then Eritoran</description>
        </group>
        <group group_id="P2">
          <title>Obese Group - Eritoran - D5W</title>
          <description>Obese subjects randomized to receive Eritoran first, then D5W.</description>
        </group>
        <group group_id="P3">
          <title>Diabetes (T2DM) Group - D5W - Eritoran</title>
          <description>T2DM subjects randomized to receive D5W first then Eritoran</description>
        </group>
        <group group_id="P4">
          <title>Diabetes (T2DM) Group - Eritoran - D5W</title>
          <description>T2DM subjects randomized to receive Eritoran first then D5W</description>
        </group>
        <group group_id="P5">
          <title>Lean Group - D5W - Eritoran</title>
          <description>Lean subjects randomized to receive D5W first then Eritoran</description>
        </group>
        <group group_id="P6">
          <title>Lean Group - Eritoran - D5W</title>
          <description>Lean subjects randomized to receive Eritoran first then d5W</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Infusion1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (3-4weeks Between Infusions)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Infusion2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Obese Group</title>
          <description>Subjects with BMI &gt;30 kg/m2 were enrolled to receive two infusions, the order of which was randomly assigned.</description>
        </group>
        <group group_id="B2">
          <title>Type 2 Diabetic Subjects</title>
          <description>Subjects with BMI &gt;30 kg/m2 and 2-hour Oral Glucose Tolerance Test &gt;200mg/dL</description>
        </group>
        <group group_id="B3">
          <title>Lean/Healthy</title>
          <description>Subjects with BMI &lt;26 kg/m2 and normal glucose tolerant</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="6.0"/>
                    <measurement group_id="B2" value="55" spread="15.6"/>
                    <measurement group_id="B3" value="19" spread="0"/>
                    <measurement group_id="B4" value="53" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.1" spread="1.8"/>
                    <measurement group_id="B2" value="33.5" spread="3.3"/>
                    <measurement group_id="B3" value="19" spread="0"/>
                    <measurement group_id="B4" value="31.5" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>Percentage of glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" spread="0.2"/>
                    <measurement group_id="B2" value="6.3" spread="0.7"/>
                    <measurement group_id="B3" value="5.3" spread="0"/>
                    <measurement group_id="B4" value="5.6" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting plasma glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.1" spread="0.8"/>
                    <measurement group_id="B2" value="6.9" spread="0.7"/>
                    <measurement group_id="B3" value="4.5" spread="0"/>
                    <measurement group_id="B4" value="5.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Eritoran on Muscle Insulin Sensitivity</title>
        <description>Muscle insulin sensitivity = muscle insulin sensitivity is determined by euglycemic hyperinsulinemic clamp procedure. M value (mg glucose / kg of body weight / minute) calculated from the clamp is measured. Higher M value indicates better insulin sensitivity. There is no established reference range.</description>
        <time_frame>72 hours</time_frame>
        <population>Data from T2DM subjects and Lean subject were not collected for primary outcome measure because of insufficient number of participants in the 2 groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Obese Group - Placebo</title>
            <description>Obese subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O2">
            <title>Obese Group - Eritoran</title>
            <description>Obese subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
          <group group_id="O3">
            <title>Diabetes (T2DM) Group - Placebo</title>
            <description>T2DM subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O4">
            <title>Diabetes (T2DM) Group - Eritoran</title>
            <description>T2DM subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
          <group group_id="O5">
            <title>Lean - Placebo</title>
            <description>Lean subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O6">
            <title>Lean - Eritoran</title>
            <description>Lean subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Eritoran on Muscle Insulin Sensitivity</title>
          <description>Muscle insulin sensitivity = muscle insulin sensitivity is determined by euglycemic hyperinsulinemic clamp procedure. M value (mg glucose / kg of body weight / minute) calculated from the clamp is measured. Higher M value indicates better insulin sensitivity. There is no established reference range.</description>
          <population>Data from T2DM subjects and Lean subject were not collected for primary outcome measure because of insufficient number of participants in the 2 groups.</population>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="0.9"/>
                    <measurement group_id="O2" value="10.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of Eritoran on Hepatic Insulin Sensitivity</title>
        <description>Hepatic insulin sensitivity = is determined by euglycemic hyperinsulinemic clamp procedure. Endogenous glucose production or EGP (mg/kg/min) calculated from the clamp is measured. Lower EGP indicates better hepatic insulin sensitivity. There is no established reference range.</description>
        <time_frame>72 hours</time_frame>
        <population>Data from T2DM subjects and Lean subject were not collected for primary outcome measure because of insufficient number of participants in the 2 groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Obese Group - Placebo</title>
            <description>Obese subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O2">
            <title>Obese Group - Eritoran</title>
            <description>Obese subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
          <group group_id="O3">
            <title>Diabetes (T2DM) Group - Placebo</title>
            <description>T2DM subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O4">
            <title>Diabetes (T2DM) Group - Eritoran</title>
            <description>T2DM subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
          <group group_id="O5">
            <title>Lean - Placebo</title>
            <description>Lean subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O6">
            <title>Lean - Eritoran</title>
            <description>Lean subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Eritoran on Hepatic Insulin Sensitivity</title>
          <description>Hepatic insulin sensitivity = is determined by euglycemic hyperinsulinemic clamp procedure. Endogenous glucose production or EGP (mg/kg/min) calculated from the clamp is measured. Lower EGP indicates better hepatic insulin sensitivity. There is no established reference range.</description>
          <population>Data from T2DM subjects and Lean subject were not collected for primary outcome measure because of insufficient number of participants in the 2 groups.</population>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.2"/>
                    <measurement group_id="O2" value="1.9" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Eritoran on TLR4 Expression in Muscle Tissue</title>
        <description>TLR4 expression in muscle tissue is determined by RNAseq using arbitrary units. Higher TLR4 expression indicates higher inflammatory response. There is no reference range.</description>
        <time_frame>72 hours</time_frame>
        <population>The total number of obese subjects enrolled is 9. However, we were only able to obtain muscle biopsies from 7 subjects. In addition, data from T2DM subjects and Lean subject were not collected for this secondary outcome measure because of insufficient number of participants in the 2 groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Obese Group - Placebo</title>
            <description>Obese subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O2">
            <title>Obese Group - Eritoran</title>
            <description>Obese subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
          <group group_id="O3">
            <title>Diabetes (T2DM) Group - Placebo</title>
            <description>T2DM subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O4">
            <title>Diabetes (T2DM) Group - Eritoran</title>
            <description>T2DM subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
          <group group_id="O5">
            <title>Lean - Placebo</title>
            <description>Lean subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O6">
            <title>Lean - Eritoran</title>
            <description>Lean subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Eritoran on TLR4 Expression in Muscle Tissue</title>
          <description>TLR4 expression in muscle tissue is determined by RNAseq using arbitrary units. Higher TLR4 expression indicates higher inflammatory response. There is no reference range.</description>
          <population>The total number of obese subjects enrolled is 9. However, we were only able to obtain muscle biopsies from 7 subjects. In addition, data from T2DM subjects and Lean subject were not collected for this secondary outcome measure because of insufficient number of participants in the 2 groups.</population>
          <units>AU</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.11"/>
                    <measurement group_id="O2" value="1.16" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Eritoran on TLR4 Expresison in Adipose Tissue</title>
        <description>TLR4 expression in the adipose tissue is determined by RNAseq using arbitrary units. Higher TLR4 expression indicates higher inflammatory response. There is no reference range.</description>
        <time_frame>72 hours</time_frame>
        <population>The total number of obese subjects enrolled is 9. However, we were only able to obtain fat biopsies from 4 subjects. In addition, data from T2DM subjects and Lean subject were not analyzed for this secondary outcome measure because of insufficient number of participants in the 2 groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Obese Group - Placebo</title>
            <description>Obese subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O2">
            <title>Obese Group - Eritoran</title>
            <description>Obese subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
          <group group_id="O3">
            <title>Diabetes (T2DM) Group - Placebo</title>
            <description>T2DM subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O4">
            <title>Diabetes (T2DM) Group - Eritoran</title>
            <description>T2DM subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
          <group group_id="O5">
            <title>Lean - Placebo</title>
            <description>Lean subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O6">
            <title>Lean - Eritoran</title>
            <description>Lean subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Eritoran on TLR4 Expresison in Adipose Tissue</title>
          <description>TLR4 expression in the adipose tissue is determined by RNAseq using arbitrary units. Higher TLR4 expression indicates higher inflammatory response. There is no reference range.</description>
          <population>The total number of obese subjects enrolled is 9. However, we were only able to obtain fat biopsies from 4 subjects. In addition, data from T2DM subjects and Lean subject were not analyzed for this secondary outcome measure because of insufficient number of participants in the 2 groups.</population>
          <units>AU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.11"/>
                    <measurement group_id="O2" value="1.22" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Eritoran on TLR4 Expression in Peripheral Blood Monocytes</title>
        <description>TLR4 expression in the peripheral blood monocytes is determined by flow cytometry using arbitrary units. Higher TLR4 expression indicates higher inflammatory response. There is no reference range.</description>
        <time_frame>72 hours</time_frame>
        <population>Data from T2DM subjects and Lean subject were not analyzed because the number of participants was insufficient in the 2 groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Obese Group - Placebo</title>
            <description>Obese subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O2">
            <title>Obese Group - Eritoran</title>
            <description>Obese subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
          <group group_id="O3">
            <title>Diabetes (T2DM) Group - Placebo</title>
            <description>T2DM subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O4">
            <title>Diabetes (T2DM) Group - Eritoran</title>
            <description>T2DM subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
          <group group_id="O5">
            <title>Lean - Placebo</title>
            <description>Lean subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O6">
            <title>Lean - Eritoran</title>
            <description>Lean subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Eritoran on TLR4 Expression in Peripheral Blood Monocytes</title>
          <description>TLR4 expression in the peripheral blood monocytes is determined by flow cytometry using arbitrary units. Higher TLR4 expression indicates higher inflammatory response. There is no reference range.</description>
          <population>Data from T2DM subjects and Lean subject were not analyzed because the number of participants was insufficient in the 2 groups.</population>
          <units>AU</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.1"/>
                    <measurement group_id="O2" value="1.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Eritoran on Plasma TNF-alpha (Tumor Necrosis Factor-alpha) Concentration</title>
        <description>TNF-alpha levels are determined by ELISA. Higher level indicates higher inflammatory response. There is no established reference range.</description>
        <time_frame>72 hours</time_frame>
        <population>Data from T2DM subjects and Lean subject were not analyzed because the number of participants was insufficient in the 2 groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Obese Group - Placebo</title>
            <description>Obese subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O2">
            <title>Obese Group - Eritoran</title>
            <description>Obese subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
          <group group_id="O3">
            <title>Diabetes (T2DM) Group - Placebo</title>
            <description>T2DM subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O4">
            <title>Diabetes (T2DM) Group - Eritoran</title>
            <description>T2DM subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
          <group group_id="O5">
            <title>Lean - Placebo</title>
            <description>Lean subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O6">
            <title>Lean - Eritoran</title>
            <description>Lean subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Eritoran on Plasma TNF-alpha (Tumor Necrosis Factor-alpha) Concentration</title>
          <description>TNF-alpha levels are determined by ELISA. Higher level indicates higher inflammatory response. There is no established reference range.</description>
          <population>Data from T2DM subjects and Lean subject were not analyzed because the number of participants was insufficient in the 2 groups.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.3"/>
                    <measurement group_id="O2" value="2.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Eritoran on Intramyocellular Diacylglycerol and Ceramide Content</title>
        <description>Intramyocellular diacylglycerol and ceramide content are determined by mass spectrometry. Higher levels have been associated with diabetes.</description>
        <time_frame>72 hours</time_frame>
        <population>Data were not collected due to lack of funding.</population>
        <group_list>
          <group group_id="O1">
            <title>Obese Group - Placebo</title>
            <description>Obese subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O2">
            <title>Obese Group - Eritoran</title>
            <description>Obese subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
          <group group_id="O3">
            <title>Diabetes (T2DM) Group - Placebo</title>
            <description>T2DM subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O4">
            <title>Diabetes (T2DM) Group - Eritoran</title>
            <description>T2DM subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
          <group group_id="O5">
            <title>Lean - Placebo</title>
            <description>Lean subjects - IV administration of D5W (5% Dextrose in water)</description>
          </group>
          <group group_id="O6">
            <title>Lean - Eritoran</title>
            <description>Lean subjects - IV administration of Eritoran 12 mg every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Eritoran on Intramyocellular Diacylglycerol and Ceramide Content</title>
          <description>Intramyocellular diacylglycerol and ceramide content are determined by mass spectrometry. Higher levels have been associated with diabetes.</description>
          <population>Data were not collected due to lack of funding.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>19 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Obese Group - Placebo</title>
          <description>Obese subjects - IV administration of D5W (5% Dextrose in water)</description>
        </group>
        <group group_id="E2">
          <title>Obese Group - Eritoran</title>
          <description>Obese subjects - IV administration of Eritoran 12 mg every 12 hours</description>
        </group>
        <group group_id="E3">
          <title>Diabetes (T2DM) Group - Placebo</title>
          <description>T2DM subjects - IV administration of D5W (5% Dextrose in water)</description>
        </group>
        <group group_id="E4">
          <title>Diabetes (T2DM) Group - Eritoran</title>
          <description>T2DM subjects - IV administration of Eritoran 12 mg every 12 hours</description>
        </group>
        <group group_id="E5">
          <title>Lean/Healthy Group - Placebo</title>
          <description>Lean subjects - IV administration of D5W (5% Dextrose in water)</description>
        </group>
        <group group_id="E6">
          <title>Lean/Healthy Group - Eritoran</title>
          <description>Lean subjects - IV administration of Eritoran 12 mg every 12 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis Grade 1, 2 or 3</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hanyu Liang</name_or_title>
      <organization>University of Texas Health San Antonio</organization>
      <phone>210-617-5300 ext 15197</phone>
      <email>liangh0@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

